Amedeo Smart

Free Medical Literature Service

 

Amedeo

Peptic Ulcer
  Free Subscription

Articles published in
J Gastroenterol Hepatol
    August 2026
  1. XUE F, Zhao S, Han P
    Comment on "High-Dose Oral Omeprazole Versus Continuous Intravenous Pantoprazole in Patients With High-Risk Peptic Ulcer Bleeding".
    J Gastroenterol Hepatol. 2026 Aug 4. doi: 10.1111/jgh.70640.
    >> Share

    July 2026
  2. KHAN A, Khokhar ME, Kumari D, Dawani P, et al
    Is Duration the Only Variable? Methodological Considerations in Comparing 10- and 14-Day Vonoprazan-Based Helicobacter pylori Therapy.
    J Gastroenterol Hepatol. 2026 Jul 28. doi: 10.1111/jgh.70628.
    >> Share

  3. CHOWDHARY R, Prasad S, Koo TH, Liu BDX, et al
    Burden of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive US Healthcare Analysis.
    J Gastroenterol Hepatol. 2026 Jul 22. doi: 10.1111/jgh.70609.
    >> Share

  4. SRIYUDTHSAK K, Nalinthassanai N, Sriapiraksa B, Rattanachaisit P, et al
    High-Dose Oral Omeprazole Versus Continuous Intravenous Pantoprazole in Patients With High-Risk Peptic Ulcer Bleeding: A Single-Blinded Multicenter RCT.
    J Gastroenterol Hepatol. 2026 Jul 12. doi: 10.1111/jgh.70566.
    >> Share

  5. PASSOS PRC, Filho VOC, Noronha MM, Maia MCB, et al
    Eradication of Helicobacter pylori With Vonoprazan-Amoxicillin Dual Therapy as an Alternative for Bismuth-Based Quadruple Therapy: A Systematic Review and Noninferiority Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Jul 11. doi: 10.1111/jgh.70565.
    >> Share

  6. FATIMA B
    Comment on "Association of Proton Pump Inhibitor and Potassium-Competitive Acid Blocker Use With Discontinuation and Intolerance of Oral 5-Aminosalicylic Acid in Patients With Ulcerative Colitis".
    J Gastroenterol Hepatol. 2026 Jul 6. doi: 10.1111/jgh.70562.
    >> Share

  7. JUNG YS, Jeon S, Park B, Moon CM, et al
    Preventive Effect of Helicobacter pylori Treatment on Colorectal Cancer Incidence and Mortality.
    J Gastroenterol Hepatol. 2026 Jul 1. doi: 10.1111/jgh.70532.
    >> Share

    June 2026
  8. ZHOU BG, Xu YM, Xu WJ, Liu J, et al
    Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.
    J Gastroenterol Hepatol. 2026 Jun 18. doi: 10.1111/jgh.70498.
    >> Share

  9. SALMAN MS, Waqar S, Nisa NU, Umair S, et al
    Reporting Inconsistency and Interpretive Caution in a Multicenter Trial of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication.
    J Gastroenterol Hepatol. 2026 Jun 17. doi: 10.1111/jgh.70513.
    >> Share

  10. MAYORI F
    Comment on: Efficacy and Safety of Quadruple Therapy With Semisynthetic Tetracycline for Helicobacter pylori Eradication: A Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Jun 8. doi: 10.1111/jgh.70492.
    >> Share

  11. AFZAL S, Afzal N, Afzal S
    Brief Critique on "Efficacy and Safety of Quadruple Therapy With Semisynthetic Tetracycline for Helicobacter pylori Eradication": A Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Jun 5. doi: 10.1111/jgh.70491.
    >> Share

  12. ANAND T, Anand N
    The Importance of Strain-Specific Variability in Evaluating Helicobacter pylori and Barrett's Esophagus Association.
    J Gastroenterol Hepatol. 2026 Jun 5. doi: 10.1111/jgh.70484.
    >> Share

    May 2026
  13. KOUNTOURAS J, Kazakos E, Hourpouliadis I, Vardaka E, et al
    Helicobacter pylori and Porphyromonas gingivalis Infections as Potential Risk Predictors for Gastric Cancer and Two Types of Esophageal Cancer.
    J Gastroenterol Hepatol. 2026 May 31. doi: 10.1111/jgh.70464.
    >> Share

  14. YAR S, Ashfaq T, Nag IS, Ahlawat D, et al
    Mechanism, Association, and Actionable Evidence: Comment on Engin et al. on Helicobacter pylori and Extra-Gastric Cancer Risk.
    J Gastroenterol Hepatol. 2026 May 15. doi: 10.1111/jgh.70432.
    >> Share

  15. RIAZ A, Kaisrani A
    "Comment on: Efficacy and Safety of Semisynthetic Tetracycline Containing Quadruple Therapy for Helicobacter pylori Eradication".
    J Gastroenterol Hepatol. 2026 May 11. doi: 10.1111/jgh.70424.
    >> Share

  16. JIANG W
    Noninferiority of 14-THA for Helicobacter pylori Eradication: Reconsidering the Evidence.
    J Gastroenterol Hepatol. 2026 May 10. doi: 10.1111/jgh.70431.
    >> Share

    April 2026
  17. ENGIN ED, Engin AB, Engin A
    Immune Evasion of Helicobacter pylori and Extra-Gastric Cancer Risk.
    J Gastroenterol Hepatol. 2026 Apr 13. doi: 10.1111/jgh.70376.
    >> Share

  18. ALSALEH T, Ferreira CN, Akram H, Jose C, et al
    Ten vs. 14 Days of Vonoprazan-Based Therapy for Helicobacter pylori: Systematic Review and Meta-Analysis of Randomized Trials.
    J Gastroenterol Hepatol. 2026 Apr 9. doi: 10.1111/jgh.70367.
    >> Share

  19. KOUNTOURAS J, Polyzos SA, Kazakos E, Doulberis M, et al
    Helicobacter pylori Infection as a Potential Risk Factor for Barrett's Esophagus.
    J Gastroenterol Hepatol. 2026 Apr 8. doi: 10.1111/jgh.70389.
    >> Share

    March 2026
  20. LEELAKUSOLVONG S, Chua TS, Quach DT, Ong AM, et al
    Rationalizing Proton Pump Inhibitor Use: Southeast Asia Consensus Recommendations.
    J Gastroenterol Hepatol. 2026 Mar 26. doi: 10.1111/jgh.70350.
    >> Share

  21. GUO QQ, Zhang J, Zhu XJ, Li WY, et al
    Efficacy and Safety of Quadruple Therapy With Semisynthetic Tetracycline for Helicobacter pylori Eradication: A Meta-Analysis.
    J Gastroenterol Hepatol. 2026 Mar 19. doi: 10.1111/jgh.70348.
    >> Share

  22. KOUNTOURAS J, Polyzos SA, Kazakos E, Lazaraki G, et al
    A Potential Impact of Helicobacter pylori Infection on Gastroesophageal Reflux Disease.
    J Gastroenterol Hepatol. 2026 Mar 10. doi: 10.1111/jgh.70327.
    >> Share

  23. TAN JT, Mao X, Cheung CL, Ooi PH, et al
    Effects of Successful Versus Delayed/Failed Helicobacter pylori Eradication Therapy on Subsequent Fracture Risk: a Population-Based Cohort Study.
    J Gastroenterol Hepatol. 2026 Mar 8. doi: 10.1111/jgh.70310.
    >> Share

    February 2026
  24. NISHIDA H
    Comment on "Helicobacter pylori Screening and Eradication in Junior High School Students in Yokosuka, Japan: Prevalence, Eradication Rates, and Challenges" (J Gastroenterol Hepatol 2025; 40:2499-2506).
    J Gastroenterol Hepatol. 2026 Feb 6. doi: 10.1111/jgh.70284.
    >> Share

    January 2026
  25. SANTO P, Meine GC, Prado RMG, Pessorrusso F, et al
    Hemostatic Powder for Non-Malignant Upper Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Gastroenterol Hepatol. 2026 Jan 23. doi: 10.1111/jgh.70249.
    >> Share

    December 2025
  26. OTANI K, Lai WY, Liou JM, Fujiwara Y, et al
    Antibiotic Resistance in Helicobacter pylori in the Asia-Pacific Region: A Call for Coordinated Regional Strategies.
    J Gastroenterol Hepatol. 2025 Dec 30. doi: 10.1111/jgh.70227.
    >> Share

  27. ICHITA C, Kusano C, Gotoda T, Hagiwara Y, et al
    Prevalence and Incidence of Gastric Cancer Among Helicobacter pylori-Naive Individuals in Japan: A Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2025 Dec 29. doi: 10.1111/jgh.70217.
    >> Share

  28. CHIANG TH, Chuang SL, Chu TC, Lee YC, et al
    Population-Based Helicobacter pylori Screening for Gastric Cancer Prevention: Opportunities and Challenges in Asia.
    J Gastroenterol Hepatol. 2025 Dec 22. doi: 10.1111/jgh.70209.
    >> Share

  29. FAN Y, Li C, Zhang W, Shi J, et al
    Fourteen-and Ten-Day Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Eradication-A Noninferiority, Multicenter, Randomized Controlled Trial.
    J Gastroenterol Hepatol. 2025 Dec 10. doi: 10.1111/jgh.70180.
    >> Share

  30. JANG Y, Park J, Kang D, Kim JH, et al
    Safety of Potassium-Competitive Acid Blockers Compared With Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease and Peptic Ulcer Disease: A Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2025 Dec 2. doi: 10.1111/jgh.70178.
    >> Share

  31. CHENG Y, Ye Q, He M, Ma W, et al
    Randomized Comparison of Vonoprazan-Amoxicillin Dual Therapy Versus Bismuth Quadruple Therapies for Helicobacter pylori Eradication: A Multicenter Trial Evaluating National Centralized Drug Procurement Antibiotics.
    J Gastroenterol Hepatol. 2025 Dec 2. doi: 10.1111/jgh.70179.
    >> Share

    November 2025
  32. LIU J, He C
    Comment on Helicobacter pylori Infection Associated With an Increased Incidence of Cholelithiasis: A Retrospective Real-World Cohort Study of 50 832 Patients.
    J Gastroenterol Hepatol. 2025 Nov 30. doi: 10.1111/jgh.70115.
    >> Share

  33. NG QX, Zhou KX, Siah KTH
    Protective or Perplexing? Rethinking the Helicobacter pylori-GERD Relationship.
    J Gastroenterol Hepatol. 2025 Nov 6. doi: 10.1111/jgh.70159.
    >> Share

    October 2025
  34. MAHESHWARI P
    Letter to the Editor Regarding "Asia-Pacific Survey on the Management of Helicobacter pylori Infection".
    J Gastroenterol Hepatol. 2025 Oct 2. doi: 10.1111/jgh.70092.
    >> Share

    September 2025
  35. OTANI K, Hang DV, Pittayanon R, Liu H, et al
    Response to the Letter by Dr. Parena Maheshwari Regarding Our Manuscript, "Asia-Pacific Survey on the Management of Helicobacter pylori Infection".
    J Gastroenterol Hepatol. 2025 Sep 25. doi: 10.1111/jgh.70087.
    >> Share

  36. KOUNTOURAS J, Zavos C, Vardaka E, Kazakos E, et al
    Helicobacter pylori and Metabolic Syndrome-Related Mast Cells May Be Potential Risk Factors for the Increased Prevalence of Barrett's Esophagus.
    J Gastroenterol Hepatol. 2025 Sep 16. doi: 10.1111/jgh.70076.
    >> Share


  37. Correction to "Vonoprazan is Superior to Lansoprazole for Healing of Severe but Not Mild Erosive Esophagitis: A Systematic Review With Meta-Analysis of Randomized Controlled Trials".
    J Gastroenterol Hepatol. 2025 Sep 5. doi: 10.1111/jgh.70063.
    >> Share

  38. SAITO Y, Saito H, Matsuda T, Nishikawa Y, et al
    Helicobacter pylori Screening and Eradication in Junior High School Students in Yokosuka, Japan: Prevalence, Eradication Rates, and Challenges.
    J Gastroenterol Hepatol. 2025 Sep 3. doi: 10.1111/jgh.70067.
    >> Share

    July 2025
  39. KOH JH, Anna O, Teng JJR, R R, et al
    Over-the-Scope Clip Versus Standard Endoscopic Treatment in Patients With Acute Nonvariceal Upper Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2025 Jul 30. doi: 10.1111/jgh.70022.
    >> Share

  40. DAI D, Quan X, Zheng Y, Wang Y, et al
    A Multisite Fusion-Based Deep Convolutional Neural Network for Classification of Helicobacter pylori Infection Status Using Endoscopic Images: A Multicenter Study.
    J Gastroenterol Hepatol. 2025 Jul 19. doi: 10.1111/jgh.70004.
    >> Share

  41. WANG H, Qu Y, Lin Y, Liu Z, et al
    Helicobacter pylori Infection and Eradication in Relation to Gastroesophageal Reflux Disease.
    J Gastroenterol Hepatol. 2025 Jul 15. doi: 10.1111/jgh.70009.
    >> Share

    May 2025
  42. SHIBATA H, Fujiyoshi T, Kawata N, Obayashi T, et al
    Vonoprazan or Proton Pump Inhibitor for Gastric Endoscopic Submucosal Dissection in Patients Taking Antithrombotic Agents.
    J Gastroenterol Hepatol. 2025 May 27. doi: 10.1111/jgh.17027.
    >> Share

  43. JING W, Yan H, Xia S, Wang Z, et al
    A Rare Case of Refractory Duodenal Ulcer With Progressive Aggravation Despite Conventional Treatment.
    J Gastroenterol Hepatol. 2025 May 16. doi: 10.1111/jgh.17007.
    >> Share

    April 2025
  44. BAIK M, Jeon J, Yoo J, Kim J, et al
    Effect of Potassium-Competitive Acid Blockers on Upper Gastrointestinal Bleeding in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study.
    J Gastroenterol Hepatol. 2025 Apr 27. doi: 10.1111/jgh.16989.
    >> Share


  45. Correction to "Endoscopic Versus Medical Management of Peptic Ulcers With Adherent Clots: Overcoming Hesitation Through Education".
    J Gastroenterol Hepatol. 2025 Apr 21. doi: 10.1111/jgh.16983.
    >> Share

  46. SI YT, Xiong XS, Zhang SK, Lai JX, et al
    Detection of Helicobacter pylori Infection and Antibiotic Resistance via String Test Coupled With qPCR Method: A Comparative Methodological Study.
    J Gastroenterol Hepatol. 2025 Apr 2. doi: 10.1111/jgh.16962.
    >> Share

    March 2025
  47. WU J, Liao Y
    Balancing Benefits and Risks: The Role of Tranexamic Acid in Upper Gastrointestinal Bleeding.
    J Gastroenterol Hepatol. 2025 Mar 15. doi: 10.1111/jgh.16941.
    >> Share

    February 2025
  48. JEARTH V
    Management of Helicobacter pylori Infection: Do We Completely See Eye to Eye?
    J Gastroenterol Hepatol. 2025 Feb 6. doi: 10.1111/jgh.16904.
    >> Share

    December 2024
  49. OTANI K, Hang DV, Pittayanon R, Liu H, et al
    Asia-Pacific Survey on the Management of Helicobacter pylori Infection.
    J Gastroenterol Hepatol. 2024 Dec 26. doi: 10.1111/jgh.16862.
    >> Share

  50. KAN SW, Tan YP, Tay MZ, Chi MJ, et al
    Tranexamic Acid With Acid Suppression Versus Acid Suppression Alone as Therapy for Upper Gastrointestinal Bleeding: A Meta-Analysis of Randomized Controlled Trials.
    J Gastroenterol Hepatol. 2024 Dec 4. doi: 10.1111/jgh.16842.
    >> Share

  51. FUKASE H, Futagami S, Yamamoto T, Masaoka T, et al
    Investigation of the effects of a new transdermal formulation of systemic diclofenac on the upper gastrointestinal mucosa in patients with low back pain: A comparative study with oral diclofenac.
    J Gastroenterol Hepatol. 2024;39:2504-2510.
    >> Share

    November 2024
  52. LIN A, Lin Z, Liu Y, Chen S, et al
    Ten-day versus 14-day vonoprazan-amoxicillin high-dose dual therapy for Helicobacter pylori eradication in China: A multicenter, open-label, randomized study.
    J Gastroenterol Hepatol. 2024 Nov 24. doi: 10.1111/jgh.16761.
    >> Share

  53. KAZAKOS E, Kountouras J
    Helicobacter pylori Infection and Cholelithiasis.
    J Gastroenterol Hepatol. 2024 Nov 18. doi: 10.1111/jgh.16820.
    >> Share

  54. JUNG YS, Jung BW, Park CH
    Comparative efficacy of Helicobacter pylori eradication therapy between tegoprazan-based concomitant and bismuth quadruple therapies: A real-world evidence.
    J Gastroenterol Hepatol. 2024 Nov 18. doi: 10.1111/jgh.16798.
    >> Share

    October 2024
  55. TAN JT, Cheung CL, Cheung KS
    Relationship between Helicobacter pylori infection, osteoporosis, and fracture.
    J Gastroenterol Hepatol. 2024;39:2006-2017.
    >> Share

    September 2024
  56. HO CT, Tan EH, Lee PC, Su CW, et al
    Reply to "Association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy: concerns to be addressed".
    J Gastroenterol Hepatol. 2024 Sep 19. doi: 10.1111/jgh.16754.
    >> Share

  57. TANG WZ, Li JZ, Liu TH
    Evaluating vonoprazan bismuth-containing triple therapy versus quadruple therapy for Helicobacter pylori.
    J Gastroenterol Hepatol. 2024 Sep 18. doi: 10.1111/jgh.16753.
    >> Share

    August 2024
  58. JUNG BW, Park CH, Jung YS
    Efficacy and safety of tegoprazan- and rabeprazole-based concomitant therapies for Helicobacter pylori infection: Real-world evidence.
    J Gastroenterol Hepatol. 2024 Aug 26. doi: 10.1111/jgh.16719.
    >> Share

  59. PAVONI M, Fiorini G, Zullo A, Saracino IM, et al
    Effectiveness of high-dose esomeprazole or pantoprazole 10-day sequential therapy empirically prescribed in Helicobacter pylori-infected naive patients: a retrospective study.
    J Gastroenterol Hepatol. 2024 Aug 26. doi: 10.1111/jgh.16731.
    >> Share

  60. ISHIBASHI F, Suzuki S, Kobayashi K, Tanaka R, et al
    Cost-effective endoscopic screening for gastric cancer in a cohort with low Helicobacter pylori prevalence.
    J Gastroenterol Hepatol. 2024 Aug 9. doi: 10.1111/jgh.16715.
    >> Share

  61. LIU J, Yin M, Lv C, Wang W, et al
    Post-reflux swallow-induced peristaltic wave index and mean nocturnal baseline impedance predict proton pump inhibitor response in patients with reflux hypersensitivity.
    J Gastroenterol Hepatol. 2024 Aug 8. doi: 10.1111/jgh.16718.
    >> Share

  62. HAYASAKA J, Hoteya S, Takazawa Y, Kikuchi D, et al
    Antacids and reflux esophagitis as a risk factor for gastric neoplasm of fundic-gland type: A retrospective, matched case-control study.
    J Gastroenterol Hepatol. 2024;39:1580-1585.
    >> Share

    July 2024
  63. BIAN J, Sang X
    Association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy: Concerns to be addressed.
    J Gastroenterol Hepatol. 2024 Jul 25. doi: 10.1111/jgh.16694.
    >> Share

  64. LIANG JW, Xiong S, Jia YG, Xiao D, et al
    Comparison of vonoprazan bismuth-containing triple therapy with quadruple therapy in Helicobacter pylori-infected treatment-naive patients: a prospective multicenter randomized controlled trial.
    J Gastroenterol Hepatol. 2024 Jul 16. doi: 10.1111/jgh.16679.
    >> Share

    June 2024
  65. ALLO G, Nierhoff D, Kasper P
    Endoscopic versus medical management of peptic ulcers with adherent clots: Overcoming hesitation through education.
    J Gastroenterol Hepatol. 2024 Jun 18. doi: 10.1111/jgh.16665.
    >> Share

  66. HO CT, Fu CC, Tan EC, Kao WY, et al
    The association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy.
    J Gastroenterol Hepatol. 2024 Jun 12. doi: 10.1111/jgh.16640.
    >> Share

  67. WEI MH, Chen CC, Lee HC, Lee YC, et al
    Prevalence of functional esophageal disorders and associated clinical characteristics in patients with proton-pump-inhibitor-unresponsive reflux symptoms.
    J Gastroenterol Hepatol. 2024 Jun 11. doi: 10.1111/jgh.16654.
    >> Share

    May 2024
  68. TASSONE D, Kazi S, Lee T, Gilmore R, et al
    Systematic review and meta-analysis of endoscopic versus medical management of peptic ulcers with adherent clots.
    J Gastroenterol Hepatol. 2024 May 31. doi: 10.1111/jgh.16611.
    >> Share

  69. SCHUBERT JP, Tay A, Lee KHC, Leong LEX, et al
    Genomic analysis of Helicobacter pylori in Australia: Antimicrobial resistance, phylogenetic patterns, and virulence factors.
    J Gastroenterol Hepatol. 2024 May 29. doi: 10.1111/jgh.16636.
    >> Share

  70. SONODA M, Matsumura T, Dao HV, Shiko Y, et al
    A prediction model of abnormal acid reflux in gastroesophageal reflux disease.
    J Gastroenterol Hepatol. 2024 May 15. doi: 10.1111/jgh.16602.
    >> Share

  71. KOUNTOURAS J, Zavos C, Vardaka E, Kyrailidi F, et al
    Helicobacter pylori and metabolic syndrome-related adipokines in nonalcoholic fatty liver disease pathophysiology.
    J Gastroenterol Hepatol. 2024 May 9. doi: 10.1111/jgh.16621.
    >> Share

  72. LOOSEN SH, Killer A, Luedde T, Roderburg C, et al
    Helicobacter pylori infection associated with an increased incidence of cholelithiasis: A retrospective real-world cohort study of 50 832 patients.
    J Gastroenterol Hepatol. 2024 May 7. doi: 10.1111/jgh.16597.
    >> Share

  73. CHEUNG KS, Yan VKC, Ye X, Hung IFN, et al
    Proton pump inhibitors associated with severe COVID-19 among two-dose but not three-dose vaccine recipients.
    J Gastroenterol Hepatol. 2024 May 5. doi: 10.1111/jgh.16601.
    >> Share

  74. ZHAO X, Ciren Y, Wu D
    Gastrointestinal: A rare intra-abdominal hydatid cyst manifesting as an acute massive upper gastrointestinal bleeding.
    J Gastroenterol Hepatol. 2024 May 2. doi: 10.1111/jgh.16579.
    >> Share

    February 2024
  75. SOGABE M, Okahisa T, Kagawa M, Sei M, et al
    Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study.
    J Gastroenterol Hepatol. 2024 Feb 29. doi: 10.1111/jgh.16530.
    >> Share

  76. YAMAOKA Y
    Revolution of Helicobacter pylori treatment.
    J Gastroenterol Hepatol. 2024 Feb 27. doi: 10.1111/jgh.16526.
    >> Share

  77. KIM NH, Chang Y, Ryu S, Sohn CI, et al
    Impact of metabolic unhealthiness and its changes on the risk of erosive esophagitis: a cohort study.
    J Gastroenterol Hepatol. 2024 Feb 21. doi: 10.1111/jgh.16519.
    >> Share

  78. SIMADIBRATA DM, Lesmana E, Fass R
    Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
    J Gastroenterol Hepatol. 2024 Feb 14. doi: 10.1111/jgh.16486.
    >> Share

  79. AYAR MS, Baydin A, Ustaoglu M, Caliskan F, et al
    Inferior vena cava collapsibility index and stroke volume as predictors of blood transfusion in upper gastrointestinal bleeding in the emergency department.
    J Gastroenterol Hepatol. 2024 Feb 9. doi: 10.1111/jgh.16500.
    >> Share

    January 2024
  80. SIMADIBRATA DM, Lesmana E, Fass R
    A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
    J Gastroenterol Hepatol. 2024 Jan 23. doi: 10.1111/jgh.16475.
    >> Share

  81. ZHUANG Q, Liao A, He Q, Liu C, et al
    The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study.
    J Gastroenterol Hepatol. 2024 Jan 22. doi: 10.1111/jgh.16471.
    >> Share

  82. MUFTAH M, Hartnett DA, Flanagan R, Redd WD, et al
    Allergic phenotype identified on allergen testing is associated with proton pump inhibitor nonresponse in eosinophilic esophagitis.
    J Gastroenterol Hepatol. 2024 Jan 7. doi: 10.1111/jgh.16469.
    >> Share

    November 2023
  83. SUN Y, Zhang A, Zuo M, Chen J, et al
    A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database.
    J Gastroenterol Hepatol. 2023 Nov 14. doi: 10.1111/jgh.16411.
    >> Share

  84. BAILEY ME, Borges LF, Goldberg HJ, Hathorn KE, et al
    Abnormal bolus reflux on impedance-pH testing independently predicts 3-year pulmonary outcome and mortality in pulmonary fibrosis.
    J Gastroenterol Hepatol. 2023;38:1998-2005.
    >> Share

  85. NABI Z, Ramchandani M, Basha J, Inavolu P, et al
    Per-oral endoscopic myotomy in cases with prior Heller's myotomy: Outcomes at a median follow-up of 5 years.
    J Gastroenterol Hepatol. 2023;38:2035-2039.
    >> Share

    October 2023
  86. SHIMAMURA Y, Inoue H, Tanabe M, Ushikubo K, et al
    Clinical outcomes of anti-reflux mucosal ablation for gastroesophageal reflux disease: An international bi-institutional study.
    J Gastroenterol Hepatol. 2023 Oct 3. doi: 10.1111/jgh.16370.
    >> Share

    September 2023
  87. ZENG SY, Wang J, Liu J, Lin MJ, et al
    Efficacy and safety of a 14-day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study.
    J Gastroenterol Hepatol. 2023 Sep 13. doi: 10.1111/jgh.16348.
    >> Share

    August 2023
  88. YU Y, Liao Z, Jiang X, Pan J, et al
    The use of magnet-controlled capsule endoscopy as the initial diagnostic tool in patients with acute upper gastrointestinal bleeding.
    J Gastroenterol Hepatol. 2023 Aug 3. doi: 10.1111/jgh.16310.
    >> Share

  89. OHKI D, Tsuji Y, Kuroda R, Ushiku T, et al
    Gastrointestinal: A case of significant esophageal ulceration due to oral iron pill therapy.
    J Gastroenterol Hepatol. 2023;38:1241.
    >> Share

    July 2023
  90. YOU N, Chen Y, Yan X, Gu B, et al
    Persistent Helicobacter pylori infection leads to elevated fasting plasma glucose level: A retrospective cohort study based on a nondiabetes Chinese population.
    J Gastroenterol Hepatol. 2023 Jul 4. doi: 10.1111/jgh.16275.
    >> Share

    June 2023
  91. EL HAGE CHEHADE N, Fu Y, Ghoneim S, Shah S, et al
    Association between obstructive sleep apnea and gastroesophageal reflux disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023 Jun 10. doi: 10.1111/jgh.16245.
    >> Share

    April 2023
  92. GULIYARA MA, Ermerak G, Levy M, Koo JH, et al
    Frailty predicts mortality in patients with Upper Gastrointestinal bleed: A prospective cohort study.
    J Gastroenterol Hepatol. 2023 Apr 1. doi: 10.1111/jgh.16188.
    >> Share

    March 2023
  93. CHANG A, Rugivarodum M, Pungpipattrakul N, Akarapatima K, et al
    Role of Oral Iron Supplementation for Anemia Secondary to Acute Nonvariceal Upper Gastrointestinal Bleeding: A Randomized Controlled Trial.
    J Gastroenterol Hepatol. 2023 Mar 30. doi: 10.1111/jgh.16185.
    >> Share

  94. SARUTA Y, Watanabe K, Tsuji T, Takahashi Y, et al
    Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors.
    J Gastroenterol Hepatol. 2023 Mar 7. doi: 10.1111/jgh.16169.
    >> Share

  95. MATSUURA N, Kato M, Irino T, Hirata K, et al
    Gastrointestinal: Ten-millimeter advanced duodenal cancer with a gastric phenotype.
    J Gastroenterol Hepatol. 2023;38:347.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016